Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
IART - Integra LifeSciences Holdings Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$20.50
DETAILS
HIGH:
$25.00
LOW:
$19.00
MEDIAN:
$19.00
CONSENSUS:
$20.50
UPSIDE:
23.35%
Stock News
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
3 Stocks Showing Breakout Potential Ahead of August
Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences Q2 Earnings Call Highlights
Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.
Integra LifeSciences (IART) Q2 Earnings Top Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.
Integra LifeSciences Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.
Here's Why Integra LifeSciences (IART) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Kaskela Law Firm Announces Investigation of Integra LifeSciences (IART) and Encourages Long-Term IART Shareholders with Investment Losses to Contact the Firm
Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (âIntegraâ) on beha
Kaskela Law Firm Announces Investigation of Integra LifeSciences (IART) and Encourages Long-Term IART Shareholders with Investment Losses to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/cases/integra-lifesciences/ Recently a securities fraud complaint was filed against Integra on behalf of investors who purchased shares of the company's stock between March 11, 2019 and May 22, 2023 (the “Wrongdoing Period”.
IART vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Integra LifeSciences Holdings Corporation (IART) Soars to 52-Week High, Time to Cash Out?
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open.
IART Stock Surges 52.1% in a Year: What's Driving the Rally?
Integra LifeSciences has climbed 52.1% in a year as growth across both segments, improved execution and transformation efforts continue to boost results.
Here's Why Integra LifeSciences (IART) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integra (IART) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Integra (IART) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Price Targets
Integra LifeSciences initiated with a Neutral at UBS
$19.00
(was $19.53)
UBS
Integra LifeSciences price target raised to $19 from $14 at Truist
$19.00
(was $19.75)
Truist Financial
BMO starts 'show-me story' Integra LifeSciences with a Market Perform
$19.00
(was $17.30)
BMO Capital
Integra LifeSciences upgraded to Buy from Hold at Argus
$25.00
(was $17.20)
Argus Research
Integra LifeSciences price target lowered to $12 from $13 at Truist
$12.00
(was $11.01)
Richard Newitter
·
Truist Financial
Integra LifeSciences price target raised to $15 from $13 at Truist
$15.00
(was $14.76)
Truist Financial
BTIG Upgrades Integra LifeSciences (IART) to Neutral
$20.00
(was $17.43)
Ryan Zimmerman
·
BTIG
Integra LifeSciences price target lowered to $26 from $32 at Truist
$26.00
(was $24.59)
Richard Newitter
·
Truist Financial
Citi Downgrades Integra LifeSciences (IART) to Sell
$23.00
(was $25.42)
Joanne Wuensch
·
Citigroup
Integra LifeSciences downgraded to Sell from Neutral at BTIG
$22.00
(was $25.42)
Ryan Zimmerman
·
BTIG
Integra LifeSciences price target raised to $32 from $25 at Truist
$32.00
(was $29.84)
Richard Newitter
·
Truist Financial
Integra LifeSciences (IART) PT Lowered to $25 at Truist Securities
$25.00
(was $23.14)
Richard Newitter
·
Truist Financial
Integra LifeSciences price target lowered to $40 from $49 at JMP Securities
$40.00
(was $23.14)
David Turkaly
·
JMP Securities
Wells Fargo Downgrades Integra LifeSciences (IART) to Equal Weight
$25.00
(was $23.14)
Vik Chopra
·
Wells Fargo
Piper Sandler keeps Neutral on Integra after results, favors Conmed and Tandem
$50.00
(was $46.85)
Matt O'Brien
·
Piper Sandler
Piper Sandler Cuts Price Target For Integra Lifesciences As It Divests Wound Care Portfolio
$55.00
(was $56.53)
FY22 EPS
·
Piper Sandler
Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (NASDAQ: IART), Marinus (NASDAQ: MRNS) and ObsEva SA (NASDAQ: OBSV)
$86.00
(was $70.95)
Anthony Petrone
·
Jefferies
Integra LifeSciences price target raised to $74 from $68 at Wells Fargo
$74.00
(was $75.07)
Shagun Singh Chadha
·
RBC Capital
Integra LifeSciences (IART) PT Raised to $74 at Wells Fargo
$74.00
(was $75.07)
Larry Biegelsen
·
Wells Fargo